Table 3 Frequency of positivity for anti-CarP antibodies in relation to positive/negative ACPA or anti-CCP2 antibodies
Pre-symptomatic individuals | RA patients | |||
|---|---|---|---|---|
Antibodies against | Number (%) | Anti- CarP + number (%) | Number (%) | Anti- CarP + number (%) |
All individuals | 423 (100) | 59 (13.9) | 188 (100) | 81 (42.2) |
CCP2 + | 151 (35.7) | 45 (29.8) | 141 (74.6) | 74 (52.5) |
CCP2 - | 272 (64.3) | 14 (5.1) | 48 (25.4) | 5 (10.4) |
CEP-1 + | 116 (28) | 32 (27.6) | 128 (68.1) | 68 (53.1) |
CEP-1 - | 299 (72) | 24 (8.1) | 60 (31.9) | 11 (18.3) |
CitC1 + | 59 (14.2) | 18 (30.5) | 63 (33.5) | 38 (60.3) |
CitC1 - | 356 (85.8) | 38 (10.7) | 125 (66.5) | 41 (32.8) |
Fibß36–52 + | 101 (24.4) | 24 (23.8) | 122 (64.9) | 66 (54.1) |
Fibß36–52 - | 313 (75.6) | 31 (9.9) | 66 (35.1) | 13 (19.7) |
Fibß62-81a(72)+ | 38 (9.2) | 5 (13.2) | 28 (14.9) | 16 (57.1) |
Fibß62-81a(72) - | 377 (90.8) | 51 (13.5) | 160 (85.1) | 63 (39.4) |
Fibß62-81b(74)+ | 65 (15.7) | 20 (30.8) | 67 (35.6) | 36 (53.7) |
Fibß62-81b(74) - | 350 (84.3) | 36 (10.3) | 121 (64.4) | 43 (35.5) |
Fibα580-600 + | 32 (7.7) | 9 (28.1) | 27 (14.4) | 16 (59.3) |
Fibα580-600- | 383 (92.3) | 47 (12.3) | 161 (85.6) | 63 (39.1) |
Fibα563-583 + | 36 (8.7) | 9 (25) | 65 (34.6) | 43 (66.2) |
Fibα563-583 - | 379 (91.3) | 47 (12.4) | 123 (65.4) | 36 (29.3) |
Fil307-324 + | 110 (26.5) | 27 (24.5) | 88 (46.8) | 48 (54.5) |
Fil307-324 - | 305 (73.5) | 29 (9.5) | 100 (53.2) | 31 (31) |
Vim 2–17 + | 25 (6) | 4 (16) | 22 (11.7) | 10 (45.5) |
Vim 2–17 - | 390 (94) | 52 (13.3) | 166 (88.3) | 69 (41.6) |
Vim 60–75 + | 38 (9.2) | 9 (23.7) | 56 (29.8) | 35 (62.5) |
Vim 60-75- | 377 (90.8) | 47 (12.5) | 132 (70.2) | 44 (33.3) |